Related references
Note: Only part of the references are listed.Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial
Hanneke C. Kluin-Nelemans et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Preetesh Jain et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
James N. Gerson et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)
Alexandra Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
Jia Ruan et al.
BLOOD (2018)
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
S. Le Gouill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
Dai Chihara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial
Simon Rule et al.
HAEMATOLOGICA (2016)
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial
Simon Rule et al.
HAEMATOLOGICA (2016)
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Christian W. Eskelund et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
Olivier Hermine et al.
LANCET (2016)
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Tadeusz Robak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Jia Ruan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study
Anna Abrahamsson et al.
BLOOD (2014)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Distribution of Lymphoid Neoplasms in China Analysis of 4,638 Cases According to the World Health Organization Classification
Jian Sun et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
Francesco Merli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
Christian H. Geisler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma
Robert Griffiths et al.
BLOOD (2011)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
